Preventing Ovarian Hyperstimulation Syndrome (OHSS): Modern Stimulation Control and Agonist Triggers

Ovarian Hyperstimulation Syndrome (OHSS) is one of the most significant complications associated with controlled ovarian stimulation during assisted reproductive treatments. Although advances in reproductive medicine have dramatically reduced its incidence, OHSS remains an important clinical concern, particularly among women undergoing in vitro fertilization (IVF).

The development of individualized stimulation protocols, improved monitoring techniques, and the widespread adoption of GnRH agonist triggers have transformed the prevention and management of OHSS. Modern fertility treatments now focus on maximizing pregnancy outcomes while ensuring patient safety.

This article explores contemporary strategies for preventing Ovarian Hyperstimulation Syndrome (OHSS), emphasizing stimulation control and the role of agonist triggers.

Understanding Ovarian Hyperstimulation Syndrome (OHSS)

OHSS is an iatrogenic complication that occurs when the ovaries respond excessively to fertility medications used during ovarian stimulation.

Excessive ovarian stimulation causes:

• Enlargement of the ovaries
• Increased vascular permeability
• Fluid shifts from blood vessels into body cavities

In severe cases, OHSS may lead to serious complications requiring hospitalization.

Fortunately, severe OHSS has become increasingly uncommon with modern reproductive protocols.

Pathophysiology of OHSS

The primary mechanism underlying OHSS involves increased production of vasoactive substances, particularly vascular endothelial growth factor (VEGF).

Following ovarian stimulation:

1. Multiple follicles develop simultaneously.
2. Trigger medications induce final oocyte maturation.
3. Ovarian cells release VEGF.
4. VEGF increases vascular permeability.
5. Fluid leaks into the abdominal and pleural cavities.

This fluid shift may result in:

• Ascites
• Hemoconcentration
• Electrolyte imbalance
• Reduced blood volume

Understanding these mechanisms has guided the development of preventive strategies.

Risk Factors for OHSS

Identifying high-risk patients before treatment is essential.

Major risk factors include:

Patient-Related Risk Factors

• Polycystic Ovary Syndrome (PCOS)
• Young age
• Low body weight
• Previous OHSS history
• High Anti-Müllerian Hormone (AMH) levels
• High antral follicle count

Cycle-Related Risk Factors

• Rapidly rising estradiol levels
• Excessive follicular development
• Large numbers of retrieved oocytes
• Use of human chorionic gonadotropin (hCG) triggers

Early identification enables clinicians to individualize treatment protocols.

Clinical Features of OHSS

Symptoms vary according to severity.

Mild Symptoms

Patients may experience:

• Abdominal bloating
• Mild pelvic discomfort
• Nausea
• Ovarian enlargement

Moderate Symptoms

Symptoms may include:

• Significant abdominal distension
• Vomiting
• Weight gain
• Ultrasound-detected ascites

Severe Symptoms

Severe OHSS may present with:

• Severe abdominal pain
• Shortness of breath
• Marked ascites
• Oliguria
• Hemoconcentration
• Thromboembolic complications

Prompt medical evaluation is necessary when severe symptoms occur.

Modern Approaches to OHSS Prevention

Current reproductive medicine emphasizes prevention rather than treatment.

Several evidence-based strategies have significantly reduced OHSS incidence.

Individualized Controlled Ovarian Stimulation

Personalized ovarian stimulation protocols are now considered standard practice.

Clinicians tailor medication regimens according to:

• Age
• Body mass index (BMI)
• AMH levels
• Antral follicle count
• Previous stimulation response

Individualization helps minimize excessive ovarian response.

Low-Dose Gonadotropin Stimulation

Women at high risk for OHSS often receive:

• Lower starting gonadotropin doses
• Gradual dose adjustments

This approach limits excessive follicular recruitment.

Preference for GnRH Antagonist Protocols

The introduction of GnRH antagonist protocols has significantly improved safety.

Advantages include:

• Lower OHSS incidence
• Flexible cycle management
• Compatibility with agonist triggers

Compared with traditional GnRH agonist protocols, antagonist regimens are generally preferred for high-risk patients.

Intensive Cycle Monitoring

Close monitoring during ovarian stimulation is essential.

Ultrasound Monitoring

Serial transvaginal ultrasounds assess:

• Number of developing follicles
• Follicular growth patterns
• Ovarian size

Hormonal Monitoring

Serum estradiol measurements help evaluate ovarian response.

Very high estradiol concentrations may indicate increased OHSS risk.

Frequent monitoring allows timely treatment adjustments.

Coasting: Temporary Withdrawal of Gonadotropins

Coasting refers to temporarily withholding gonadotropin medications while continuing cycle monitoring.

The goal is to:

• Reduce estradiol levels
• Allow smaller follicles to regress
• Lower OHSS risk

Coasting may be considered in selected high-risk patients.

GnRH Agonist Triggers: A Major Advancement

One of the most important advances in OHSS prevention is the use of GnRH agonist triggers for final oocyte maturation.

Traditional hCG Trigger

Historically, hCG was routinely used to induce oocyte maturation.

However, hCG:

• Produces prolonged ovarian stimulation
• Increases VEGF secretion
• Significantly elevates OHSS risk

GnRH Agonist Trigger

In GnRH antagonist cycles, clinicians may administer a GnRH agonist trigger instead of hCG.

Benefits include:

• Shorter luteinizing hormone surge
• Reduced VEGF production
• Dramatic reduction in OHSS incidence

The use of agonist triggers has been described as a major milestone in reproductive medicine.

Freeze-All Strategy

Modern IVF programs increasingly utilize a freeze-all strategy in high-risk patients.

This approach involves:

1. Retrieval of mature oocytes.
2. Fertilization and embryo development.
3. Cryopreservation of all embryos.
4. Delayed embryo transfer in a later cycle.

Advantages include:

• Substantial reduction in late OHSS risk
• Improved endometrial receptivity in selected patients

Freeze-all protocols are particularly beneficial for women with PCOS.

Adjuvant Pharmacological Interventions

Certain medications may further reduce OHSS risk.

Dopamine Agonists

Cabergoline may reduce vascular permeability by inhibiting VEGF-mediated pathways.

Potential benefits include:

• Reduced ascites formation
• Lower OHSS severity

Metformin in PCOS

Women with PCOS may benefit from Metformin therapy before IVF.

Studies suggest Metformin may:

• Improve metabolic function
• Reduce excessive ovarian response
• Lower OHSS incidence

Medication use should always occur under specialist supervision.

Post-Retrieval Monitoring

Patients remain at risk for OHSS even after oocyte retrieval.

Important post-procedure recommendations include:

• Adequate hydration
• Daily weight monitoring
• Observation for worsening symptoms
• Prompt reporting of breathing difficulties or severe pain

Early intervention improves outcomes.

The Future of OHSS Prevention

Advances in reproductive medicine continue to improve patient safety.

Emerging developments include:

• Artificial intelligence-assisted stimulation protocols
• Precision medicine approaches
• Novel biomarkers for risk prediction
• Enhanced individualized treatment algorithms

The ultimate goal is the complete elimination of severe OHSS.

Counseling and Shared Decision-Making

Patient education remains an essential aspect of OHSS prevention.

Women undergoing IVF should receive counseling regarding:

• Individual risk factors
• Warning signs and symptoms
• Available preventive strategies
• Expected treatment outcomes

Shared decision-making enhances treatment safety and patient satisfaction.

Conclusion

Preventing Ovarian Hyperstimulation Syndrome (OHSS) is a central objective in modern reproductive medicine. Through individualized stimulation protocols, careful monitoring, GnRH antagonist cycles, agonist triggers, and freeze-all strategies, clinicians can dramatically reduce the risk of this potentially serious complication.

The widespread adoption of evidence-based prevention strategies has transformed IVF safety, allowing most women to undergo fertility treatment with excellent outcomes and minimal risk. Continued advances in personalized reproductive care promise even greater improvements in patient safety in the future.